Heart Disease: Prevention and Management — The Complete Evidence-Based Guide

Table of contents

• Evidence summary
• What heart disease is
• All forms and types
• Prevention priorities
• Management after diagnosis
• Supplements with evidence
• Side effects
• Interactions
• What works and what does not
• Sources and funding notes

Evidence summary

Claim	Best evidence	Funding / conflict trace	Strength
Most cardiovascular disease is preventable through risk-factor control.	WHO identifies tobacco, unhealthy diet, obesity, inactivity, harmful alcohol use, air pollution, raised blood pressure, raised blood glucose, and raised blood lipids as major modifiable risks (World Health Organization)).	WHO is an intergovernmental public-health body; institutional incentive is global disease surveillance and prevention, not supplement sales.	Strong
Cardiovascular health is multidimensional.	AHA Life’s Essential 8 includes diet, physical activity, nicotine exposure, sleep health, body mass index, blood lipids, blood glucose, and blood pressure (AHA Life’s Essential 8, AHA advisory).	AHA statement lists NIH grants; AHA has institutional public-health and guideline influence incentives, so recommendations are treated as consensus framework rather than product evidence.	Strong framework
Mediterranean-style diets reduce major cardiovascular events in high-risk adults.	PREDIMED reanalysis found fewer major cardiovascular events with Mediterranean diets supplemented with olive oil or nuts than a reduced-fat control diet in 7,447 high-risk adults (PREDIMED reanalysis).	Funded by Instituto de Salud Carlos III, Spanish Ministry of Health, and others; protocol deviations required correction and republished analysis, so evidence is strong but not flawless.	Strong
Reducing saturated fat modestly lowers cardiovascular-event risk when replacement foods are appropriate.	Cochrane’s 2020 review found reduced combined cardiovascular events with saturated-fat reduction, especially when saturated fat was replaced with polyunsaturated fat (Cochrane saturated-fat review, PubMed record).	WHO funded the update; authors reported no known conflicts. WHO funding aligns with public nutrition guidance but is still disclosed.	Moderate–strong
Physical activity lowers cardiovascular and mortality risk.	A dose-response meta-analysis of 196 articles covering 94 cohorts and more than 30 million participants found higher non-occupational physical activity associated with lower cardiovascular disease and mortality risk (physical activity meta-analysis).	Public and charitable funding included MRC and Wellcome Trust; no exercise-product sponsor signal in PubMed funding fields.	Strong observational
Smoking cessation after coronary disease reduces recurrent risk.	Cochrane’s secondary-prevention review examined adults with coronary heart disease and found quitting smoking reduces cardiovascular death and major adverse cardiovascular events compared with continuing smoking (Cochrane smoking cessation review).	British Heart Foundation funding; no tobacco-cessation product sponsor found in PubMed record.	Strong
Blood-pressure treatment reduces major cardiovascular events.	A Lancet systematic review of 123 studies and 613,815 participants found blood-pressure-lowering treatment reduces major cardiovascular disease events, coronary heart disease, stroke, heart failure, renal failure, and all-cause mortality across many baseline groups (Lancet BP meta-analysis).	Funded by NIHR and Oxford Martin School; no single antihypertensive manufacturer sponsor listed in PubMed funding field.	Strong
LDL-cholesterol lowering reduces vascular events.	The Cholesterol Treatment Trialists’ individual-participant meta-analysis found statin LDL reduction lowered major vascular events by about 21% per 1 mmol/L LDL-C reduction (CTT meta-analysis).	Funded by British Heart Foundation, UK Medical Research Council, Cancer Research UK, European Community Biomed Programme, and Australian public/heart foundations; statin class is commercial but this evidence synthesis was not presented as a single-brand trial.	Strong
Exercise-based cardiac rehabilitation improves outcomes after coronary events.	Cochrane’s 2021 review evaluated exercise-based cardiac rehabilitation in coronary heart disease and reported clinical and quality-of-life benefits versus no-exercise control (Cochrane cardiac rehabilitation review).	Public MRC/Chief Scientist Office funding listed; no rehab-device manufacturer funding found in PubMed record.	Strong
Better medication adherence is associated with fewer events and deaths.	A dose-response meta-analysis found each 20% increment in cardiovascular medication adherence was associated with lower cardiovascular events, stroke, and all-cause mortality (cardiovascular adherence meta-analysis).	PubMed abstract does not show a commercial sponsor; observational adherence evidence can still be confounded by healthy-adherer behavior.	Moderate

What heart disease is

“Heart disease” is an umbrella term, not one diagnosis. WHO classifies cardiovascular diseases as disorders of the heart and blood vessels, including coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, and venous thromboembolism (World Health Organization)). The prevention logic is similar across many forms: reduce atherosclerosis-driving exposures, detect risk early, and treat measured risk factors instead of guessing from symptoms. WHO states that cardiovascular disease caused an estimated 19.8 million deaths in 2022, about 32% of global deaths, with heart attack and stroke accounting for 85% of those deaths (World Health Organization)). Heart risk stackThe biggest wins usually come from stacking small proven controls.Do not smoke or vape nicotineNicotine exposure is a core AHA cardiovascular-health metric.Control blood pressureBP lowering has randomized-trial evidence for fewer CVD events.Lower LDL when indicatedLDL reduction lowers major vascular events.Move + eat well + sleepLifestyle changes reinforce each other rather than acting alone.

Text version of infographic: Heart risk stack

Item	Meaning
Nicotine exposure	Avoid tobacco and secondhand smoke; quitting after CHD lowers recurrent events.
Blood pressure	Measured and treated blood pressure is one of the best-supported risk levers.
LDL cholesterol	Lowering LDL cholesterol reduces major vascular events in large trial meta-analysis.
Lifestyle cluster	Diet, activity, sleep, glucose control, body weight, and stress management work as a system.

All forms and grades

Type	What it means	Main prevention / management focus	Evidence caveat
Coronary heart disease	Narrowing or dysfunction of blood vessels supplying the heart muscle.	LDL-C, blood pressure, tobacco cessation, glucose control, antiplatelet/statin/other clinician-directed medicines, cardiac rehab after events.	Most supplement evidence targets risk markers, not hard coronary outcomes.
Heart attack / myocardial infarction	Heart muscle injury, usually from reduced blood flow.	Emergency care, secondary prevention medicines, rehab, smoking cessation, risk-factor control.	Do not substitute supplements for acute symptoms or prescribed secondary-prevention care.
Heart failure	The heart cannot pump or fill well enough for the body’s needs.	Guideline-directed medicines, salt/fluid guidance when prescribed, monitored exercise, symptom tracking, device/procedure care when indicated.	CoQ10 has adjunct evidence but is not a replacement for heart-failure medicines (Cochrane CoQ10 review).
Arrhythmias	Abnormal heart rhythm, including atrial fibrillation.	Diagnosis, rhythm/rate management, stroke prevention, electrolyte review, sleep-apnea evaluation when suspected.	High-dose omega-3 has been linked with atrial fibrillation signals in some trials, so rhythm history matters (NIH ODS omega-3 fact sheet).
Valve disease	Heart valves are narrowed or leaky.	Imaging follow-up, symptom monitoring, procedures when indicated.	Lifestyle supports overall risk but cannot “clean” or repair a structurally damaged valve.
Congenital heart disease	Heart structure differences present from birth.	Specialist follow-up, activity guidance, pregnancy planning when relevant.	Adult prevention principles still apply, but individualized cardiology care dominates.

Prevention priorities

1. Use a dietary pattern, not a single “heart food”

The best-supported heart diet pattern is high in vegetables, fruit, beans, lentils, whole grains, nuts, seeds, unsaturated fats, and minimally processed foods, while limiting trans fat, excess saturated fat, refined carbohydrates, and excess salt. PREDIMED supports a Mediterranean-style pattern for high-risk adults, while Cochrane supports saturated-fat reduction most when replacement calories come from unsaturated fats rather than refined carbohydrate (PREDIMED reanalysis, Cochrane saturated-fat review). Original insight: the food swap matters more than the subtraction. Replacing butter with olive oil, nuts, seeds, avocado, or other unsaturated-fat foods is a different intervention from replacing butter with refined starch; the first usually improves LDL-related risk, while the second may not.

2. Move enough to change risk, then add strength

A large dose-response meta-analysis found that higher leisure-time physical activity is associated with lower incident cardiovascular disease and mortality, with benefits appearing well below elite-athlete levels (physical activity meta-analysis). A practical weekly target is a mix of aerobic activity, strength training, and less sitting, with intensity adapted to medical status and symptoms.

3. Quit tobacco completely

Tobacco cessation is one of the clearest cardiovascular interventions because smoking directly promotes thrombosis, endothelial dysfunction, inflammation, and atherosclerosis. In people with coronary heart disease, Cochrane found quitting smoking reduces cardiovascular death and major adverse cardiovascular events compared with continuing smoking (Cochrane smoking cessation review).

4. Measure and control blood pressure, lipids, and glucose

High blood pressure, raised lipids, and raised glucose are “intermediate risk factors” that can be measured and treated, and WHO explicitly lists drug treatment of hypertension, diabetes, and high blood lipids as necessary to reduce cardiovascular risk in people with those conditions (World Health Organization)). Large trial meta-analyses support BP lowering and LDL lowering as hard-outcome interventions, not just lab-number changes (Lancet BP meta-analysis, CTT meta-analysis).

5. Sleep and stress: treat them as risk amplifiers

AHA added sleep health to Life’s Essential 8 because sleep duration and quality affect cardiometabolic risk, including blood pressure, weight, glucose regulation, and health behavior consistency (AHA Life’s Essential 8, AHA advisory). Stress is not solved by a capsule, but stress management can improve adherence, smoking cessation, sleep, eating, and blood-pressure routines. Prevention pyramidBuild from proven foundations before supplement add-ons.Foundation: no tobacco + BP/LDL/glucose controlMost direct risk-factor reduction.Daily pattern: food, movement, sleepImproves several risk markers at once.Rehab and adherence after diagnosisTurns treatment plans into outcomes.Supplements only for selected targetsHelpful for some markers; rarely proven as stand-alone event prevention.

Text version of infographic: Prevention pyramid

Item	Meaning
Foundation	Avoid nicotine and control measured BP, LDL cholesterol, and glucose when abnormal.
Daily pattern	Mediterranean-style food pattern, regular activity, adequate sleep, and body-weight support.
After diagnosis	Use cardiac rehabilitation and medication adherence systems.
Supplements	Use only for evidence-matched targets and interaction checks.

Management after a diagnosis

Heart disease management is secondary prevention: stop the next event, preserve function, and improve quality of life. Exercise-based cardiac rehabilitation is the most underused high-value intervention because it combines supervised exercise, education, risk-factor management, and behavioral support; Cochrane’s updated review supports benefits in coronary heart disease (Cochrane cardiac rehabilitation review). Medication adherence is not “just compliance”; it is the mechanism by which evidence becomes protection. A dose-response meta-analysis found higher cardiovascular medication adherence associated with lower cardiovascular events, stroke, and all-cause mortality, although healthy-adherer bias remains a limitation (cardiovascular adherence meta-analysis).

Management lever	What to do	Why it matters	When to escalate
Medication adherence	Use a pill organizer, refill calendar, side-effect log, and a single medication list.	Adherence tracks with lower event and mortality risk (cardiovascular adherence meta-analysis).	Report side effects rather than stopping heart medicines abruptly.
Cardiac rehabilitation	Enroll after heart attack, stent, bypass, stable angina, or clinician-indicated heart failure care.	Exercise-based rehab improves outcomes and quality-of-life measures in CHD (Cochrane cardiac rehabilitation review).	Chest pain, fainting, severe breathlessness, or new palpitations need urgent clinical review.
Risk-factor tracking	Track BP, LDL-C/non-HDL-C or apoB where used, A1c/glucose, weight/waist, smoking status, and symptoms.	WHO identifies measured intermediate risk factors as key to early detection and management (World Health Organization)).	Rising symptoms or uncontrolled numbers despite adherence need medication review.
Lifestyle maintenance	Plan meals, movement, sleep, stress recovery, and social support as recurring systems.	AHA’s Life’s Essential 8 treats behavior and biology as one scorecard (AHA advisory).	Depression, insomnia, pain, or breathlessness often need professional support.

Supplements with evidence

Supplements should be matched to a measurable target and checked against medicines. “Natural” does not mean low-risk, and many supplement trials measure LDL, triglycerides, blood pressure, or symptoms rather than heart attacks or survival.

Supplement	Most plausible heart-related use	What evidence supports	What it does not prove	Funding / conflict trace
Omega-3 EPA/DHA	Triglyceride lowering; selected high-risk adjunct care under clinician guidance.	Cochrane found little/no effect of increased long-chain omega-3 on all-cause mortality or cardiovascular events overall, while NIH ODS notes high-dose EPA-only and mixed EPA+DHA trials have conflicting event results (Cochrane omega-3 review, NIH ODS omega-3 fact sheet).	Ordinary fish-oil capsules are not proven “heart insurance” for everyone.	Cochrane is nonprofit evidence synthesis; major high-dose product trials include industry involvement and are downgraded for product-specific claims.
CoQ10	Adjunct in selected heart-failure patients; not a replacement for guideline medicines.	Cochrane reviewed randomized trials in heart failure and found possible benefit signals, but certainty is limited by trial quality and influential industry-linked trials (Cochrane CoQ10 review).	It does not reliably lower blood pressure or prevent statin muscle symptoms for everyone (NCCIH CoQ10).	Cochrane methods are strong; several included CoQ10 trials had supplement-industry ties.
Magnesium	Correct deficiency; modest BP support in some adults.	A meta-analysis of 34 double-blind placebo-controlled trials found median 368 mg/day magnesium for 3 months reduced systolic BP by about 2.00 mmHg and diastolic BP by about 1.78 mmHg (magnesium BP meta-analysis).	It is not a stand-alone hypertension treatment and is unsafe in significant kidney disease without supervision (NIH ODS magnesium fact sheet).	PubMed record does not show supplement-company funding; NIH ODS is government reference.
Soluble fiber / psyllium / beta-glucan	LDL-C lowering and glucose/weight support when added to diet.	A 181-RCT meta-analysis found soluble fiber reduced LDL-C, total cholesterol, triglycerides, and apoB; a psyllium meta-analysis found LDL-C reduction with median-dose supplementation (soluble fiber meta-analysis, psyllium meta-analysis).	Fiber does not replace statins or BP medicines in high-risk disease.	Soluble-fiber review reported no funding; some individual fiber trials may involve product brands.
Plant sterols / stanols	LDL-C lowering through reduced intestinal cholesterol absorption.	Meta-analyses find LDL-C reductions around 5–15%, with a 124-study dose analysis supporting effects across common doses (plant sterol meta-analysis, dose-response meta-analysis).	No randomized placebo-controlled trials prove fewer heart attacks or strokes from sterols alone (plant sterol review).	Older meta-analysis included an author with consulting ties to food companies; hard-outcome evidence is absent.
Garlic	Small improvements in BP/lipids in some trials.	A 2025 meta-analysis of 108 RCTs reported improvements in several cardiovascular risk factors, and NCCIH says garlic evidence for hypertension is not strong because many studies are small or low quality (garlic RCT meta-analysis, NCCIH hypertension digest).	Garlic does not substitute for anticoagulants, statins, or BP medicines.	Meta-analysis PubMed record lists Kerman University of Medical Sciences funding; NCCIH is government reference.
Folate / folic acid	Stroke-risk reduction in low-folate settings; correction of deficiency.	Meta-analyses show folic acid lowers stroke risk more consistently than coronary heart disease risk, especially where baseline folate is low (folic acid CVD meta-analysis, folic acid stroke meta-analysis).	It is not a broad heart-attack prevention pill and can mask B12 deficiency at high supplemental intakes (NIH ODS folate fact sheet).	Folate benefits vary by baseline folate status and fortification context; this article avoids country-specific fortification guidance.

Supplement evidence mapSupplements help markers more often than events.Best marker evidencePsyllium/soluble fiber and plant sterols lower LDL-C.Selected clinical adjunctCoQ10 may help selected heart-failure patients; clinician-led.Mixed event evidenceOmega-3 event prevention depends on form, dose, and population.Avoid hypeCleanses, homeopathy, and miracle cholesterol blends lack convincing heart-outcome evidence.

Text version of infographic: Supplement evidence map

Item	Meaning
Best marker evidence	Soluble fiber and plant sterols have consistent LDL-C effects.
Selected clinical adjunct	CoQ10 has heart-failure adjunct signals but is not primary therapy.
Mixed event evidence	Omega-3 evidence is strongest for triglycerides and mixed for event prevention.
Avoid hype	Cleanses, homeopathic heart remedies, and miracle blends should not be marketed as heart disease treatments.

Risks and all side effects

Category	Common side effects	Rare but serious risks	Who needs extra caution	Independent source
Prescription heart medicines, broad class warning	Dizziness, low blood pressure, fatigue, muscle symptoms, bleeding, cough, electrolyte changes, glucose changes, or GI symptoms depending on class.	Serious bleeding with antithrombotics, very low BP, kidney/electrolyte complications, severe muscle injury with lipid-lowering drugs, allergic reactions.	Anyone with new symptoms, kidney/liver disease, pregnancy, planned surgery, frailty, or multiple medicines.	Drug-specific labeling and clinician review are required; do not stop heart medicines abruptly.
Omega-3 EPA/DHA	Fishy aftertaste, burping, GI upset, loose stools.	Bleeding caution at high doses or with anticoagulants/antiplatelets; atrial fibrillation signal in some high-dose trials.	Anticoagulant/antiplatelet users, atrial fibrillation history, fish/shellfish allergy, surgery planning.	NIH ODS omega-3 fact sheet
CoQ10	Insomnia, digestive upset, nausea, diarrhea, appetite loss.	Potential interference with warfarin anticoagulation; oncology-treatment concerns because antioxidant supplements may affect treatment effects.	Warfarin users, chemotherapy/radiation patients, pregnancy/lactation due to limited data.	NCCIH CoQ10; MSKCC CoQ10
Magnesium	Diarrhea, nausea, abdominal cramping, especially oxide/citrate salts.	Dangerous hypermagnesemia in kidney impairment or excessive dosing.	Kidney disease, older adults with reduced renal function, people using magnesium-containing laxatives/antacids.	NIH ODS magnesium fact sheet
Soluble fiber / psyllium	Bloating, gas, abdominal fullness, constipation if taken without enough fluid.	Choking or obstruction risk if dry powder is swallowed without adequate liquid; altered medication absorption is possible.	Swallowing disorders, bowel obstruction/strictures, people taking narrow-therapeutic-index medicines.	psyllium meta-analysis; AAFP interaction review
Plant sterols / stanols	Usually mild GI symptoms; possible carotenoid reductions.	Contraindicated in sitosterolemia; hard long-term event-safety evidence is incomplete.	Known or suspected sitosterolemia; children and pregnancy require individualized care.	plant sterol review
Garlic supplements	Breath/body odor, abdominal pain, flatulence, nausea, reflux.	Bleeding risk, allergic reactions, severe skin burns with raw topical garlic.	Anticoagulant/antiplatelet users, surgery planning, pregnancy/lactation beyond food amounts.	NCCIH garlic
Folic acid	Usually well tolerated; rare GI upset or hypersensitivity.	High supplemental intake can mask or worsen consequences of vitamin B12 deficiency; interactions with methotrexate and antiepileptic drugs.	B12 deficiency risk, cancer therapy, antiepileptic use, methotrexate use.	NIH ODS folate fact sheet

All interactions

Interacts with	Type	Severity	Mechanism	Action
Omega-3 × anticoagulants/antiplatelets	Supplement–drug	Use with caution	Potential additive bleeding effect at high intakes; evidence varies.	Tell clinician before high-dose omega-3, surgery, or dual antiplatelet/anticoagulant therapy (NIH ODS omega-3).
Omega-3 × atrial fibrillation history	Supplement–condition	Monitor / clinician-led	Some high-dose trials reported atrial fibrillation signals.	Avoid self-prescribing high-dose EPA/DHA with AF history (NIH ODS omega-3).
CoQ10 × warfarin	Supplement–drug	Use with caution / monitor INR	Vitamin K-like structural features may reduce anticoagulant effect in case reports.	Do not start or stop without INR plan (NCCIH CoQ10).
CoQ10 × antihypertensives / antidiabetics	Supplement–drug	Monitor	Possible additive BP or glucose lowering in susceptible users.	Track BP/glucose after initiation; adjust only with clinician.
CoQ10 × chemotherapy/radiation	Supplement–treatment	Avoid unless oncology team approves	Antioxidant activity could affect oxidative treatment mechanisms.	Ask oncology team first (MSKCC CoQ10).
Magnesium × tetracycline/quinolone antibiotics or bisphosphonates	Supplement–drug	Separate doses	Mineral binding reduces drug absorption.	Separate by several hours per product-specific instructions (NIH ODS magnesium).
Magnesium × diuretics / PPIs	Drug–nutrient	Monitor	Some diuretics increase magnesium loss; prolonged PPI use can be linked to low magnesium.	Check magnesium when clinically indicated (NIH ODS magnesium).
Psyllium/fiber × carbamazepine, lithium, digoxin, thyroid medicine, other oral drugs	Supplement–drug	Separate and monitor	Gel-forming fiber may slow or reduce absorption of some medicines.	Take medicines at a different time; ask pharmacist for narrow-therapeutic-index drugs (AAFP interaction review).
Plant sterols × bile acid sequestrants	Supplement–drug	Use with professional guidance	Both act in the gut and may affect absorption of sterols or other nutrients.	Coordinate timing and lipid monitoring (plant sterol review).
Garlic × anticoagulants/antiplatelets/NSAIDs	Supplement–drug	Use with caution; stop before surgery if advised	Antiplatelet effects and bleeding case reports.	Disclose use before surgery or anticoagulant therapy (NCCIH garlic, dietary supplements and bleeding review).
Folic acid × methotrexate, antiepileptics, antifolate drugs, B12 deficiency	Supplement–drug / supplement–condition	Clinician-led	Folate pathways overlap with methotrexate and seizure medicines; high folic acid can obscure B12-related anemia.	Use only with the prescribing clinician for cancer/autoimmune therapy or epilepsy drugs (NIH ODS folate).

What works and what does not

Claim	Verdict	Evidence	Key caveat
Mediterranean-style eating lowers heart-event risk in high-risk adults.	WORKS	PREDIMED reanalysis.	Pattern matters; not just adding olive oil or nuts to an unhealthy diet.
Exercise reduces cardiovascular risk.	WORKS	Large dose-response cohort meta-analysis.	Symptomatic or recently diagnosed patients need medical clearance.
Smoking cessation after CHD reduces recurrence risk.	WORKS	Cochrane secondary-prevention review.	Reduction is not enough; complete cessation is the goal.
Blood pressure and LDL treatment reduce events.	WORKS	Large randomized-trial meta-analyses.	Targets and medicines are individualized.
Cardiac rehabilitation after coronary events improves outcomes.	WORKS	Cochrane review.	Access and adherence determine benefit.
Ordinary fish oil prevents heart attacks in everyone.	DOESN’T, as a blanket claim	Cochrane found little/no overall event benefit.	High triglycerides and selected high-risk cases are different questions.
CoQ10 cures heart failure or replaces medicines.	DOESN’T	Cochrane shows adjunct signals only.	Use as add-on only after medication review.
Magnesium is a stand-alone BP medicine.	DOESN’T	Average BP effects are modest.	Useful when deficient; risky in kidney disease.
Plant sterols prevent heart attacks by themselves.	INSUFFICIENT EVIDENCE	LDL improves; hard-outcome trials are absent.	A marker benefit is not the same as event proof.
Detoxes, cleanses, and homeopathy treat heart disease.	DOESN’T	NCCIH finds detox evidence low quality; systematic reviews do not support homeopathy beyond placebo.	May delay proven care (NCCIH detoxes and cleanses, homeopathy systematic-review review).

What to do this weekA practical start for prevention or secondary prevention.Book measurementsBP, lipids, glucose/A1c, weight/waist, smoking status.Fix the plateVegetables, legumes, whole grains, nuts, seeds, unsaturated fats.Schedule movementAerobic + strength; cardiac rehab if eligible.Review every pill and supplementCheck adherence, side effects, and interactions.

Text version of infographic: What to do this week

Item	Meaning
Measurements	Use measured risk factors instead of guessing.
Food	Build a Mediterranean-style, minimally processed eating pattern.
Movement	Schedule aerobic and strength work or formal cardiac rehab when indicated.
Review	Bring all medicines and supplements to a clinician or pharmacist review.

Frequently asked questions

Can heart disease be prevented?

Many cardiovascular events can be prevented or delayed by controlling modifiable risks including tobacco exposure, diet quality, physical inactivity, harmful alcohol use, air pollution exposure where possible, blood pressure, blood glucose, blood lipids, and weight (World Health Organization)). Genetics, age, sex, environment, and access to care still matter, so prevention means lowering risk rather than guaranteeing immunity.

What is the best diet for heart disease prevention?

The most defensible answer is a Mediterranean-style or similarly plant-forward whole-food pattern: vegetables, fruit, legumes, whole grains, nuts, seeds, and unsaturated fats, with saturated fat reduced and replaced thoughtfully (PREDIMED reanalysis, Cochrane saturated-fat review). No single food cancels a high-risk dietary pattern.

Do supplements prevent heart attacks?

Most supplements improve risk markers, if they help at all; they rarely prove fewer heart attacks or longer life. Omega-3, soluble fiber, plant sterols, magnesium, CoQ10, garlic, and folate each have specific evidence-matched uses, but none should replace prescribed prevention or rehabilitation (Cochrane omega-3 review, Cochrane CoQ10 review).

Is cardiac rehabilitation worth it?

Yes for eligible people after coronary events or procedures. Cochrane’s updated review supports exercise-based cardiac rehabilitation for coronary heart disease, and the practical advantage is that rehab combines supervised exercise, education, and risk-factor routines rather than leaving recovery to willpower alone (Cochrane cardiac rehabilitation review).

What numbers should be tracked?

Track blood pressure, LDL-C or non-HDL-C/apoB where used, triglycerides, glucose or A1c when relevant, weight/waist trend, smoking status, exercise capacity, sleep, and symptoms. WHO identifies raised blood pressure, glucose, and lipids as measurable intermediate risk factors for heart attack, stroke, heart failure, and related complications (World Health Organization)).

What should make someone seek urgent medical care?

Chest pressure or pain, pain radiating to arm/jaw/back, sudden breathlessness, fainting, new neurologic symptoms, severe palpitations, coughing pink froth, or symptoms that feel like a prior heart event require urgent medical assessment. Supplements and lifestyle changes are prevention tools, not emergency treatments.

Sources and funding notes

Source	URL	Funding / conflict note
World Health Organization CVD fact sheet	WHO CVD fact sheet	Intergovernmental public-health source; institutional incentive is surveillance and prevention.
AHA Life’s Essential 8 advisory	PubMed 35766027	NIH grants listed; AHA consensus framework, not product evidence.
PREDIMED reanalysis	PubMed 29897866	Funded by Instituto de Salud Carlos III, Spanish Ministry of Health, and others; corrected/republished after protocol deviations.
Cochrane saturated-fat review	PubMed 32428300	WHO funded update; authors reported no known conflicts in PubMed excerpt.
Physical activity meta-analysis	PubMed 36854652	MRC/Wellcome and public/charitable funding listed.
Smoking cessation in CHD	PubMed 35938889	British Heart Foundation funding listed.
Blood-pressure lowering meta-analysis	PubMed 26724178	NIHR and Oxford Martin School funding listed.
LDL statin meta-analysis	PubMed 22607822	Public and heart-foundation funding listed.
Cardiac rehabilitation Cochrane review	PubMed 34741536	MRC/Chief Scientist Office funding listed.
Medication adherence meta-analysis	PubMed 34821699	Observational evidence; healthy-adherer bias possible.